Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

IO Biotech (NASDAQ:IOBT) announced on Monday that patients with skin tumors who received its lead cancer vaccine candidate, Cylembio, with Merck’s (NYSE:MRK) anti-PD-1 therapy, Keytruda, lived longer ...

Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...